JPWO2021111003A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021111003A5 JPWO2021111003A5 JP2022534370A JP2022534370A JPWO2021111003A5 JP WO2021111003 A5 JPWO2021111003 A5 JP WO2021111003A5 JP 2022534370 A JP2022534370 A JP 2022534370A JP 2022534370 A JP2022534370 A JP 2022534370A JP WO2021111003 A5 JPWO2021111003 A5 JP WO2021111003A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- domain
- antibodies
- derived
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 102220157709 rs144942998 Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214104.2 | 2019-12-06 | ||
| EP19214104 | 2019-12-06 | ||
| PCT/EP2020/084831 WO2021111003A1 (en) | 2019-12-06 | 2020-12-07 | Humanized cldn18.2 antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023505318A JP2023505318A (ja) | 2023-02-08 |
| JP2023505318A5 JP2023505318A5 (https=) | 2023-10-24 |
| JPWO2021111003A5 true JPWO2021111003A5 (https=) | 2023-10-24 |
| JP7641967B2 JP7641967B2 (ja) | 2025-03-07 |
Family
ID=68808161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534370A Active JP7641967B2 (ja) | 2019-12-06 | 2020-12-07 | ヒト化ｃｌｄｎ１８．２抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230030674A1 (https=) |
| EP (1) | EP4069738A1 (https=) |
| JP (1) | JP7641967B2 (https=) |
| KR (1) | KR20220111308A (https=) |
| CN (1) | CN114901696B (https=) |
| AU (1) | AU2020398045A1 (https=) |
| CA (1) | CA3159465A1 (https=) |
| WO (1) | WO2021111003A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3199830A1 (en) * | 2020-12-23 | 2022-06-30 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibody-drug conjugates |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| EP4349371A4 (en) | 2021-06-02 | 2025-06-25 | Bio-Thera Solutions, Ltd. | DRUG CONJUGATE AND USE THEREOF |
| JP2024523166A (ja) * | 2021-06-15 | 2024-06-28 | ゼンコア インコーポレイテッド | クローディン１８．２及びｃｄ３に結合するヘテロ二量体抗体 |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| WO2025077829A1 (zh) * | 2023-10-13 | 2025-04-17 | 信达细胞制药(苏州)有限公司 | Cldn18.2抗体及car-t细胞在治疗cldn18.2阳性实体瘤中的应用 |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015659A2 (en) | 1998-09-16 | 2000-03-23 | Zymogenetics, Inc. | Stomach polypeptide zsig28 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| PH12016502073B1 (en) * | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014075788A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US9953140B2 (en) * | 2013-03-15 | 2018-04-24 | Intent Solutions, Inc. | Systems, methods, and apparatuses for securely dispensing one or more prescribed substances to a securely identified intended user |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| AU2017294276B2 (en) | 2016-07-08 | 2024-08-01 | Crage Medical Co., Limited | Antibody for anti-claudin 18A2 and use thereof |
| CN115925943A (zh) * | 2017-12-27 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| JP7398380B2 (ja) | 2018-03-08 | 2023-12-14 | フェインズ セラピューティクス，インコーポレーテッド | 抗クローディン１８．２抗体及びその使用 |
| WO2019175617A1 (en) | 2018-03-10 | 2019-09-19 | Pratik Sharma | Data redundancy and elimination module |
| SG11202007074PA (en) | 2018-05-18 | 2020-08-28 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| CN114901365B (zh) * | 2019-12-23 | 2025-07-15 | 斯迪安生物技术公司 | 肿瘤特异性密蛋白18.2抗体 |
| CA3199830A1 (en) * | 2020-12-23 | 2022-06-30 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibody-drug conjugates |
| BR112023027312A2 (pt) * | 2021-06-23 | 2024-03-12 | Cytune Pharma | Imunocitocina |
| US20240350589A1 (en) * | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
-
2020
- 2020-12-07 EP EP20816527.4A patent/EP4069738A1/en active Pending
- 2020-12-07 CN CN202080091553.6A patent/CN114901696B/zh active Active
- 2020-12-07 US US17/782,417 patent/US20230030674A1/en active Pending
- 2020-12-07 AU AU2020398045A patent/AU2020398045A1/en active Pending
- 2020-12-07 JP JP2022534370A patent/JP7641967B2/ja active Active
- 2020-12-07 WO PCT/EP2020/084831 patent/WO2021111003A1/en not_active Ceased
- 2020-12-07 CA CA3159465A patent/CA3159465A1/en active Pending
- 2020-12-07 KR KR1020227022671A patent/KR20220111308A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brinkmann et al. | The making of bispecific antibodies | |
| Labrijn et al. | When binding is enough: nonactivating antibody formats | |
| JP2025142045A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| Krah et al. | Engineering bispecific antibodies with defined chain pairing | |
| JP7822587B2 (ja) | ヘテロ二量体化Ｉｇドメイン | |
| CN104185642A (zh) | 轻链桥连的双特异性抗体 | |
| CA2952532A1 (en) | Multispecific antigen binding proteins | |
| US20230114801A1 (en) | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | |
| KR20200067197A (ko) | 단일특이적 항체로부터 다중특이적 항체의 생성 방법 | |
| CN109796532B (zh) | 靶向成纤维激活蛋白α的结合单元及其应用 | |
| CN115066274A (zh) | 三价结合分子 | |
| JPWO2021111003A5 (https=) | ||
| JP2021531027A5 (https=) | ||
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| US20180371088A1 (en) | TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY | |
| JPWO2019245991A5 (https=) | ||
| EP3746480A1 (en) | Bispecific antibodies comprising an antigen-binding site binding to lag3 | |
| AU2024275316A1 (en) | Ch3 domain variant or bispecific antibody comprising same | |
| JPWO2023028657A5 (https=) | ||
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| US20250243274A1 (en) | Compositions for Redirecting Immunoglobulins to Immune Cells | |
| Wozniak-Knopp | Bispecific antibodies | |
| CN121969645A (zh) | 用于将免疫球蛋白重定向至免疫细胞的组合物 | |
| JPWO2023097024A5 (https=) |